Summit is on track to deliver top-line data from its Phase II trial of SMT 19969 for the treatment of C. difficile infection in Q4 having now completed patient enrolment. Summit is at a very exciting stage in its development having also recently met its primary objective in its Phase Ib modified diet clinical trial of SMT C1100 for Duchenne Muscular Dystrophy (DMD). Positive top line SMT 19969 Phase II data would mark a very successful H2 for the group. We remain upbeat about Summit’s future pro ....
